Cystic echinococcosis

1. Disease Information

1.1 Overview and current understanding

CE is defined as human infection by the larval stage of E. granulosus s.l. producing unilocular, fluid-filled hydatid cysts that most often localize in liver and lungs; cyst rupture can disseminate protoscolices and trigger allergic/anaphylactic reactions. (jahan2025understandingechinococcosisa pages 3-7, akbulut2025hydatiddisease pages 6-8)

1.2 Key identifiers and controlled vocabularies

• ICD-10: CE was captured using ICD-10 B67.1–B67.9 (within the B67.* echinococcosis block) in Mongolia surveillance work. (bold2024thediagnosticchallenge pages 2-4)
• WHO-IWGE classification (ultrasound-based): cysts are categorized into active (CE1, CE2), transitional (CE3a, CE3b), and inactive (CE4, CE5) stages, which guide treatment selection. (akbulut2025hydatiddisease pages 8-11)
• MeSH / MONDO / Orphanet: not explicitly reported in the retrieved full-text evidence and therefore cannot be asserted here without additional targeted retrieval.

1.3 Synonyms and alternative names

• Hydatid disease / hydatid cyst disease is used interchangeably with CE in recent clinical literature. (akbulut2025hydatiddisease pages 6-8, akbulut2025hydatiddisease pages 11-13)

1.4 Evidence source type

Information in this report is derived from aggregated disease-level resources (reviews, burden analyses) and multiple primary clinical/epidemiologic studies; several surveillance estimates explicitly note under-ascertainment when relying on surgical case series alone. (bold2024thediagnosticchallenge pages 5-7, bold2024thediagnosticchallenge pages 1-2)

2. Etiology

2.1 Disease causal factors

• Infectious agent: Echinococcus granulosus s.l. (larval stage in humans). (akbulut2025hydatiddisease pages 6-8, jahan2025understandingechinococcosisa pages 3-7)
• Life cycle context: transmission is maintained between canid definitive hosts (e.g., dogs) and herbivorous intermediate hosts (e.g., sheep/goats/cattle), with humans as accidental intermediate hosts. (jahan2025understandingechinococcosisa pages 3-7, akbulut2025hydatiddisease pages 6-8)

2.2 Risk factors (human)

Evidence from recent reviews and national studies supports the following as key risk factors: - Rural residence and dog ownership (higher exposure probability); drinking commercially sourced water was associated with lower infection risk in pooled evidence summarized in a 2024 review. (hogea2024cysticechinococcosisin pages 6-7) - Practices enabling dog infection and environmental egg contamination: dog access to infected offal and feeding dogs raw offal are repeatedly emphasized as key drivers of transmission; insufficient dog deworming is highlighted as a persistence factor in endemic settings. (jahan2025understandingechinococcosisa pages 7-10, tenzin2024theburdenand pages 2-3) - Bhutan risk context: rural living, dog ownership, feeding dogs, home slaughtering, being a farmer, and unsafe drinking water were identified as relevant risk exposures in Bhutan’s national retrospective assessment. (tenzin2024theburdenand pages 2-3)

2.3 Protective factors

Direct quantitative protective-factor evidence was limited in retrieved sources; however, reduced exposure to infected dogs/offal and improved sanitation are consistently framed as protective measures (see Prevention section). (hogea2024cysticechinococcosisin pages 6-7)

2.4 Gene–environment interactions

No validated human host genetic susceptibility or explicit gene–environment interaction findings were identified in the retrieved evidence.

3. Phenotypes

3.1 Core clinical phenotypes (symptoms/signs/lab)

• Asymptomatic or nonspecific symptoms for years due to slow cyst growth. (akbulut2025hydatiddisease pages 6-8)
• Hepatic CE phenotypes: abdominal discomfort/pain, mass effect, cholestatic/biliary complications; rupture can trigger fever/urticaria/eosinophilia/anaphylaxis. (akbulut2025hydatiddisease pages 8-11)
• Pulmonary CE phenotypes: respiratory symptoms varying by size/location; lung is the second most common organ in population data. (tenzin2024theburdenand pages 1-2)

Suggested HPO terms (non-exhaustive; mapped to typical CE manifestations): - Abdominal pain HP:0002027 - Hepatomegaly HP:0002240 - Liver cysts HP:0001407 - Pulmonary cysts HP:0033149 (or related pulmonary lesion terms depending on ontology version) - Eosinophilia HP:0001880 - Anaphylaxis HP:0100845

Phenotype timing: disease is typically chronic/insidious with prolonged asymptomatic periods. (akbulut2025hydatiddisease pages 6-8)

3.2 Frequency and organ distribution (recent data)

• Bhutan (2015–2019, n=159): liver 78%, lungs 13%; small fractions in other sites; 4 patients had both liver and lung involvement. (tenzin2024theburdenand pages 1-2, tenzin2024theburdenand pages 4-5)
• A 2024 review reiterates that hepatic disease is dominant (>70% in many summaries). (hogea2024cysticechinococcosisin pages 6-7)

3.3 Quality-of-life impact

Specific QoL instrument results (e.g., SF-36/EQ-5D) were not present in the retrieved evidence; nevertheless, CE contributes to substantial morbidity and prolonged hospitalization in national series (e.g., >47% hospitalized >4 days in Bhutan). (tenzin2024theburdenand pages 1-2)

4. Genetic/Molecular Information

4.1 Causal genes (human)

Not applicable in the Mendelian sense: CE is not a human genetic disease.

4.2 Parasite genotypes and molecular identification

The retrieved evidence included mention that isolates can be identified as E. granulosus s.l. genotypes via PCR-based methods in research settings, but systematic genotype–phenotype associations in humans were not extracted here. (mehdi2025designandevaluation pages 8-9)

4.3 Host genetic susceptibility / protective variants

No ClinVar/ClinGen/OMIM-style host causal variants were identified in the retrieved evidence.

5. Environmental Information

5.1 Environmental and lifestyle factors

Environmental contamination with parasite eggs is central; exposures are linked to rural pastoral settings, dog ownership, and slaughter/offal-handling practices. (jahan2025understandingechinococcosisa pages 3-7, tenzin2024theburdenand pages 2-3)

5.2 Infectious agent (taxonomy)

• Agent: Echinococcus granulosus sensu lato (cestode). (akbulut2025hydatiddisease pages 6-8)

6. Mechanism / Pathophysiology

6.1 Causal chain (from trigger to clinical manifestations)

1. Exposure/entry: ingestion of eggs shed in canid feces. (jahan2025understandingechinococcosisa pages 3-7)
2. Early development: eggs release oncospheres that penetrate the intestinal wall and disseminate (predominantly to liver via portal circulation; also lungs). (jahan2025understandingechinococcosisa pages 3-7)
3. Lesion formation: development of slowly enlarging hydatid cysts; growth has been described around ~1–5 cm/year and may be clinically silent for years. (akbulut2025hydatiddisease pages 6-8)
4. Host response and tissue remodeling: formation of a host-derived pericyst/adventitia and variable immune infiltration; organ dysfunction is mainly from mass effect, biliary/vascular involvement, or complications. (akbulut2025hydatiddisease pages 8-11, petrone2024evaluationofthe pages 1-2)
5. Complications: rupture can release antigenic material causing urticaria/eosinophilia/anaphylaxis and can seed secondary echinococcosis. (jahan2025understandingechinococcosisa pages 3-7, akbulut2025hydatiddisease pages 8-11)

6.2 Immune system involvement (recent human evidence; 2024)

A 2024 human study analyzing tissue and blood immune responses reported that CE lesions can persist for decades due to immune modulation. In pericyst and adjacent liver tissue, aggregates of CD3+ T cells (predominantly CD4+) and B-cell aggregates were observed; monocytes/granulocytes were rare. Tissue cytokine staining showed scarce Th2 cytokines (IL-4/IL-13) but moderate IFN-γ. In contrast, peripheral whole-blood stimulation with parasite antigen B (AgB) showed increased IL-4 responses in CE patients (p=0.003 in larger cohort confirmation), while IFN-γ responses were similar between cases and controls. (petrone2024evaluationofthe pages 1-2, petrone2024evaluationofthe pages 7-9)

Suggested ontology mappings: - GO biological processes: immune response (GO:0006955); T cell activation (GO:0042110); cytokine-mediated signaling pathway (GO:0019221); response to interferon-gamma (GO:0034341); type 2 immune response (GO:0042092). - Cell Ontology (CL) terms (examples): CD4-positive, alpha-beta T cell (CL:0000624); B cell (CL:0000236); fibroblast (CL:0000057) (for pericyst/adventitia context).

6.3 Molecular profiling / omics

No transcriptomic/proteomic/metabolomic datasets were directly extracted from the retrieved human CE evidence.

7. Anatomical Structures Affected

7.1 Organ-level involvement

• Primary: liver (dominant), lungs (second). (tenzin2024theburdenand pages 1-2)
• Other possible sites: wide anatomic range has been described (bone, kidney, spleen, soft tissue, thyroid, breast, adrenal, CNS), though frequencies vary across series; such dissemination supports broad differential consideration in endemic patients. (akbulut2025hydatiddisease pages 6-8)

Suggested UBERON terms (examples): liver (UBERON:0002107), lung (UBERON:0002048), spleen (UBERON:0002106).

7.2 Tissue/cell level

• Host-derived pericyst/adventitia and surrounding parenchyma are key sites of immune infiltration, dominated by CD4+ lymphocytes in examined hepatic cases. (petrone2024evaluationofthe pages 1-2)

7.3 Subcellular localization

Not directly addressed in retrieved evidence.

8. Temporal Development

8.1 Onset and course

• Typically chronic and insidious with long asymptomatic phases. (akbulut2025hydatiddisease pages 6-8)
• Cyst growth over years contributes to delayed diagnosis and late-stage complications in many endemic settings. (akbulut2025hydatiddisease pages 6-8)

8.2 Progression and staging

• WHO-IWGE staging divides cysts into active, transitional, and inactive categories that correspond to viability/activity and guide treatment. (akbulut2025hydatiddisease pages 8-11)

9. Inheritance and Population

9.1 Epidemiology and burden (recent quantitative data)

Key recent burden statistics include: - GBD 2019 analysis (published 2024): global ASIR changed from 2.65/100,000 (1990) to 2.60/100,000 (2019) with EAPC −0.18%; deaths and DALYs declined overall 1990–2019, but projections suggest ASIR declines while ASMR and age-standardized DALY rates may rise 2020–2030. (tian2024globalregionaland pages 1-2) - GBD 2021 figures cited in a 2025 textbook chapter: 148,521 new cases, 633,404 prevalent cases, 1,364 deaths, 105,072 DALYs with age-standardized incidence 1.82/100,000 and prevalence 7.69/100,000. (akbulut2025hydatiddisease pages 6-8) - Bhutan national retrospective burden (published 2024; 2015–2019): average annual incidence 4.4/100,000; estimated ~39 DALYs/year for treatment-seeking cases and possibly ~80 DALYs/year including non-treatment-seeking cases; liver 78%, lungs 13%. (tenzin2024theburdenand pages 1-2) - Mongolia underreporting (published 2024): predicted diagnosed burden 15.9/100,000 vs surgical-case prevalence 2.2/100,000 (i.e., surgical cases represent ~one-eighth of diagnosed burden). (bold2024thediagnosticchallenge pages 5-7, bold2024thediagnosticchallenge pages 1-2) - Population ultrasound screening synthesis (2024 review): pooled sample 130,093, 2,077 CE cases, with mean prevalence around 0.0160 (95% CI 0.0153–0.0166) in collated studies. (hogea2024cysticechinococcosisin pages 6-7)

9.2 Demographics

• Bhutan data show higher incidence among females vs males (6.11 vs 2.79 per 100,000; p<0.001) and concentration among farmers. (tenzin2024theburdenand pages 3-3)

9.3 Genetic inheritance

Not applicable.

10. Diagnostics

10.1 Imaging

• Ultrasound: primary modality for abdominal CE and the basis of WHO-IWGE staging. (akbulut2025hydatiddisease pages 8-11)
• CT/MRI/MRCP/ERCP: CT useful for calcification/anatomy; MRI for soft tissue; MRCP/ERCP for biliary involvement. (akbulut2025hydatiddisease pages 8-11)
• PET/CT: may correlate with serology and help guide benzimidazole duration in selected settings. (akbulut2025hydatiddisease pages 11-13)

10.2 Serology (recent comparative performance)

A 2024 head-to-head evaluation in 74 suspected CE sera reported: - ELISA: sensitivity 85.42%, specificity 88.46%. - IFA: sensitivity 83.33%, specificity 88.46%. - Fumouze IHA: sensitivity 70.83%, specificity 96.15%. - Siemens IHA: sensitivity 66.67%, specificity reported ~92.31% in the study summary. - Western blot: sensitivity 72.92%, specificity 88.46%. These findings support combining tests and interpreting serology alongside imaging due to false negatives/positives. (erganis2024comparisonofmethods pages 4-6)

In Mongolia’s underreporting analysis, practical diagnostic constraints were emphasized; RDTs for active cysts were reported with sensitivity 74% and specificity 96%, contrasted with ELISA 69% sensitivity / 96% specificity in that local context. (bold2024thediagnosticchallenge pages 7-8)

10.3 Molecular diagnostics (recent developments)

Emerging molecular diagnostics include: - Multiplex qPCR (QPCR-Echino): ongoing diagnostic clinical study aims to assess sensitivity of Echinococcus DNA detection in operating specimens/biopsies/puncture fluids and plasma (NCT05824442; start 2023-10-24). (NCT05824442 chunk 1) - ddPCR for circulating cfDNA: exploratory interventional study evaluating ddPCR sensitivity for plasma E. granulosus s.l. cfDNA detection in untreated hepatic CE, with sensitivity stratified by cyst stage (NCT05769790; start 2022-03-21; primary completion estimated 2024-03). (NCT05769790 chunk 1)

10.4 Differential diagnosis

Detailed differential diagnosis lists were not available in the retrieved evidence; in practice, staging-compatible imaging patterns plus serology/molecular confirmation are used to distinguish CE from non-parasitic cysts and other hepatic/pulmonary lesions.

11. Outcome / Prognosis

11.1 Mortality and recurrence

• A 2024 GBD-linked review reports post-surgical mortality about 2.2% and postoperative recurrence about 6.5% in summarized literature. (tian2024globalregionaland pages 1-2)
• In a hospital series from an endemic area of Peru (2010–2019), post-surgical recurrence was reported as 16.5% at median 32.3 months in a setting with advanced/complicated disease and incomplete staging-guided management. (akbulut2025hydatiddisease pages 8-11)

11.2 Burden and hospitalization

In Bhutan, >47% of patients were hospitalized for >4 days, and most were treated surgically (>82%). (tenzin2024theburdenand pages 1-2)

12. Treatment

12.1 Stage-based treatment concepts (WHO-IWGE)

• CE4–CE5 (inactive): typically watch-and-wait (observation). (akhan2025theroleof pages 2-4, akbulut2025hydatiddisease pages 8-11)
• CE1, CE3a: percutaneous techniques such as PAIR or standard catheterization are recommended options; albendazole is used peri-procedurally. (akhan2025theroleof pages 2-4)
• CE2, CE3b: modified catheterization (Mo-CAT) is highlighted as effective for multivesicular/daughter-cyst-rich lesions. (akhan2025theroleof pages 6-8)

12.2 Pharmacotherapy

• Albendazole (ABZ): first-line benzimidazole, typically 10–15 mg/kg/day with fatty meal; duration varies and lacks global consensus. (akbulut2025hydatiddisease pages 11-13)
• Real-world outcome (Uruguay, 2024): among 36 adults completing 5-year follow-up, ABZ-only achieved 93.75% success; ABZ+PZQ achieved 100% success in 4 patients; no deaths occurred. (rosa2024followupstudy pages 1-2)

Suggested MAXO terms (examples): albendazole therapy (MAXO term for antiparasitic drug therapy), praziquantel therapy.

12.3 Interventional radiology (real-world implementation)

A 2025 interventional radiology review emphasizes stage-specific percutaneous management: - CE1/CE3a: PAIR or catheterization; reported success up to 96% and recurrence as low as 4% overall. A meta-analysis cited found percutaneous therapy vs surgery for CE1/CE3a had lower mortality (0.1% vs 0.7%), fewer major complications (7.9% vs 25.1%), fewer minor complications (13.1% vs 33%), lower recurrence (1.6% vs 6.3%), and shorter hospital stay (2.4 vs 15 days). (akhan2025theroleof pages 6-8) - CE2/CE3b: Mo-CAT long-term series (132 cysts) reported 0 mortality, major complications 10%, recurrence 4.5%, mean hospital stay 3.8 days, mean follow-up 52 months. (akhan2025theroleof pages 6-8) A table summarizing stage-specific recurrence bands (<5% for CE1/CE3a; <5–7% for CE2/CE3b) is available in the cited review. (akhan2025theroleof media 3452c1f5)

12.4 Surgery

Surgery remains necessary for complicated disease (e.g., rupture into peritoneal/pleural cavities, complex biliary communication, infected cysts, or when percutaneous resources are unavailable). (akhan2025theroleof pages 2-4)

12.5 Ongoing/recent clinical trials (selected)

• Adjuvant ABZ after pulmonary hydatid resection: randomized trial ABZ vs placebo; primary endpoint recurrence at 6 months; start 2024-02-01 (NCT06483880). (NCT06483880 chunk 1)
• Laparoscopic vs open liver surgery: randomized non-inferiority trial, n=350, recurrence endpoint at 24 months (NCT01643018). (NCT01643018 chunk 1)
• Molecular diagnostics trials: multiplex qPCR (NCT05824442) and ddPCR cfDNA (NCT05769790) as described above. (NCT05824442 chunk 1, NCT05769790 chunk 1)

13. Prevention

13.1 Primary prevention (One Health)

A 2024 review synthesizing prevention measures emphasizes: - Preventing canid access to infected offal. - Controlling stray dogs and discouraging home slaughter. - Regular deworming of dogs with praziquantel. - Improved sanitation and public education to reduce fecal–oral exposure. - Sheep vaccination is described as used in Argentina and China (recombinant vaccine) as part of control strategies. (hogea2024cysticechinococcosisin pages 6-7)

13.2 Secondary prevention (screening/early detection)

Ultrasound-based population screening is used in endemic programs and can detect early-stage hepatic cysts; this is also relevant for burden estimation given long asymptomatic periods. (hogea2024cysticechinococcosisin pages 6-7)

13.3 Tertiary prevention

Long-term follow-up after treatment is emphasized; for example, pharmacologically treated cohorts were followed for ≥5 years under WHO-IWGE guidance in Uruguay, and percutaneous therapy reviews advocate long-term monitoring (≥10 years). (rosa2024followupstudy pages 1-2, akhan2025theroleof pages 4-6)

14. Other species / Natural disease

14.1 Species affected and zoonotic cycle

• Definitive hosts: canids (not exhaustively enumerated in retrieved evidence).
• Intermediate hosts: livestock such as sheep/goats/cattle; other domestic animals implicated in some settings.
• Humans: accidental intermediate hosts. Transmission is driven by egg shedding in canid feces and ingestion by intermediate hosts; dog infection is reinforced by consumption of infected viscera/offal. (jahan2025understandingechinococcosisa pages 3-7, tenzin2024theburdenand pages 2-3)

14.2 Veterinary relevance

CE is a One Health problem affecting humans, livestock production, and the food chain; economic burden estimates include treatment and livestock losses. (hogea2024cysticechinococcosisin pages 6-7)

15. Model organisms

Specific laboratory model organism systems for CE pathogenesis and therapy testing were not directly described in the retrieved evidence. The literature does reference experimental and animal-model immunology observations (e.g., sheep tissue regulatory cytokines), but detailed model cataloging (mouse strains, in vitro systems, etc.) was not available in the extracted full texts. (petrone2024evaluationofthe pages 2-3)

Recent developments and expert analysis (2023–2024 prioritized)

1. Burden quantification and forecasting: A 2024 GBD 2019-based analysis provides updated global incidence trends and projections to 2030, highlighting persistent burden in low-SDI regions and among women/older adults. (tian2024globalregionaland pages 1-2)
2. Surveillance and underreporting: A 2024 Mongolia analysis shows surgical-case reporting captures only ~1/8 of diagnosed burden and identifies operational weaknesses (laboratory capacity, reporting workflows, insufficient albendazole supply, limited percutaneous availability). This supports expert consensus that CE burden is often underestimated. (bold2024thediagnosticchallenge pages 5-7, bold2024thediagnosticchallenge pages 7-8)
3. Human immunopathology: A 2024 study comparing local tissue vs peripheral immune responses indicates discordant local (Th1-leaning/low Th2) vs peripheral (AgB-specific IL-4) signatures and emphasizes the adventitia/pericyst as an immunopathogenic interface. (petrone2024evaluationofthe pages 7-9)
4. Treatment effectiveness of percutaneous interventions: Stage-stratified percutaneous outcomes compiled in 2025 (with cited meta-analysis) show lower recurrence, complications, and hospital stay compared with surgery in selected CE1/CE3a cysts, and strong Mo-CAT outcomes for CE2/CE3b—supporting ongoing practice shift toward minimally invasive management when expertise is available. (akhan2025theroleof pages 6-8)

Evidence excerpts (abstract-quotable statements)

• Mongolia underreporting estimate: “the prevalence could be approximately 16 cases per 100,000 people, which is eight times higher than the number of reported surgical cases.” (bold2024thediagnosticchallenge pages 7-8)
• Bhutan incidence and burden: average annual incidence 4.4 per 100,000 and estimated ~39 DALYs/year (treatment-seeking), ~80 DALYs/year including non-treatment-seeking. (tenzin2024theburdenand pages 1-2)

Summary artifacts

The following structured tables are provided for knowledge-base ingestion.

Table: This table compiles key disease identifiers, terminology, classification, and recent epidemiology/burden estimates for cystic echinococcosis. It is useful as a quick reference for mapping the disease concept and anchoring a knowledge-base entry with current quantitative data.

Table: This table summarizes evidence-based diagnostic and treatment options for cystic echinococcosis, organized by modality and WHO-IWGE cyst stage. It highlights recent quantitative performance and outcome data, plus ongoing molecular and therapeutic clinical studies.

Limitations of this report (evidence gaps)

• MONDO, Orphanet, and exact MeSH identifiers were not found in the retrieved full-text evidence and therefore are not asserted.
• Differential diagnosis and standardized QoL instrument outcomes were not extracted from the retrieved sources.
• Model organism details were limited in available evidence.

References

1. (akbulut2025hydatiddisease pages 6-8): S Akbulut. Hydatid Disease. Springer Nature Switzerland, Jan 2025. ISBN 9783031972775. URL: https://doi.org/10.1007/978-3-031-97277-5, doi:10.1007/978-3-031-97277-5. This article has 0 citations.

2. (akbulut2025hydatiddisease pages 8-11): S Akbulut. Hydatid Disease. Springer Nature Switzerland, Jan 2025. ISBN 9783031972775. URL: https://doi.org/10.1007/978-3-031-97277-5, doi:10.1007/978-3-031-97277-5. This article has 0 citations.

3. (bold2024thediagnosticchallenge pages 1-2): Bolor Bold, Christian Schindler, Uranshagai Narankhuu, Agiimaa Shagj, Erdenebileg Bavuujav, Sonin Sodov, Tsogbadrakh Nyamdorj, and Jakob Zinsstag. The diagnostic challenge of cystic echinococcosis in humans: first assessment of underreporting rates in mongolia. Tropical Medicine and Infectious Disease, Jul 2024. URL: https://doi.org/10.3390/tropicalmed9070163, doi:10.3390/tropicalmed9070163. This article has 6 citations.

4. (jahan2025understandingechinococcosisa pages 3-7): Nusrat Jahan, Priyanka Barua, Shahela Alam, Tamanna Akter, and Hamida Khanum. Understanding echinococcosis: a review of its epidemiological outlook. Bangladesh Journal of Zoology, 53:3-18, Jun 2025. URL: https://doi.org/10.3329/bjz.v53i1.82673, doi:10.3329/bjz.v53i1.82673. This article has 1 citations.

5. (bold2024thediagnosticchallenge pages 2-4): Bolor Bold, Christian Schindler, Uranshagai Narankhuu, Agiimaa Shagj, Erdenebileg Bavuujav, Sonin Sodov, Tsogbadrakh Nyamdorj, and Jakob Zinsstag. The diagnostic challenge of cystic echinococcosis in humans: first assessment of underreporting rates in mongolia. Tropical Medicine and Infectious Disease, Jul 2024. URL: https://doi.org/10.3390/tropicalmed9070163, doi:10.3390/tropicalmed9070163. This article has 6 citations.

6. (akbulut2025hydatiddisease pages 11-13): S Akbulut. Hydatid Disease. Springer Nature Switzerland, Jan 2025. ISBN 9783031972775. URL: https://doi.org/10.1007/978-3-031-97277-5, doi:10.1007/978-3-031-97277-5. This article has 0 citations.

7. (bold2024thediagnosticchallenge pages 5-7): Bolor Bold, Christian Schindler, Uranshagai Narankhuu, Agiimaa Shagj, Erdenebileg Bavuujav, Sonin Sodov, Tsogbadrakh Nyamdorj, and Jakob Zinsstag. The diagnostic challenge of cystic echinococcosis in humans: first assessment of underreporting rates in mongolia. Tropical Medicine and Infectious Disease, Jul 2024. URL: https://doi.org/10.3390/tropicalmed9070163, doi:10.3390/tropicalmed9070163. This article has 6 citations.

8. (hogea2024cysticechinococcosisin pages 6-7): Mihai-Octav Hogea, Bogdan-Florin Ciomaga, Mădălina-Maria Muntean, Andrei-Alexandru Muntean, Mircea Ioan Popa, and Gabriela Loredana Popa. Cystic echinococcosis in the early 2020s: a review. Tropical Medicine and Infectious Disease, 9:36, Jan 2024. URL: https://doi.org/10.3390/tropicalmed9020036, doi:10.3390/tropicalmed9020036. This article has 74 citations.

9. (jahan2025understandingechinococcosisa pages 7-10): Nusrat Jahan, Priyanka Barua, Shahela Alam, Tamanna Akter, and Hamida Khanum. Understanding echinococcosis: a review of its epidemiological outlook. Bangladesh Journal of Zoology, 53:3-18, Jun 2025. URL: https://doi.org/10.3329/bjz.v53i1.82673, doi:10.3329/bjz.v53i1.82673. This article has 1 citations.

10. (tenzin2024theburdenand pages 2-3): Chador Tenzin, Tashi Dendup, P. R. Torgerson, Peter Deplazes, Sonam Zangmo, Chador Wangmo, Tsheten Tsheten, and Tandin Zangpo. The burden and distribution of cystic echinococcosis in bhutan: a retrospective study. Parasitology, pages 1-9, Nov 2024. URL: https://doi.org/10.1017/s0031182024001069, doi:10.1017/s0031182024001069. This article has 1 citations and is from a peer-reviewed journal.

11. (tenzin2024theburdenand pages 1-2): Chador Tenzin, Tashi Dendup, P. R. Torgerson, Peter Deplazes, Sonam Zangmo, Chador Wangmo, Tsheten Tsheten, and Tandin Zangpo. The burden and distribution of cystic echinococcosis in bhutan: a retrospective study. Parasitology, pages 1-9, Nov 2024. URL: https://doi.org/10.1017/s0031182024001069, doi:10.1017/s0031182024001069. This article has 1 citations and is from a peer-reviewed journal.

12. (tenzin2024theburdenand pages 4-5): Chador Tenzin, Tashi Dendup, P. R. Torgerson, Peter Deplazes, Sonam Zangmo, Chador Wangmo, Tsheten Tsheten, and Tandin Zangpo. The burden and distribution of cystic echinococcosis in bhutan: a retrospective study. Parasitology, pages 1-9, Nov 2024. URL: https://doi.org/10.1017/s0031182024001069, doi:10.1017/s0031182024001069. This article has 1 citations and is from a peer-reviewed journal.

13. (mehdi2025designandevaluation pages 8-9): Abolfazl Masoumi Koushk Mehdi, H. Motedayyen, M. Fasihi Harandi, Hossein Akbari, Amin Moradi Hasan-Abad, and Mohsen Arbabi. Design and evaluation of a novel direct hemagglutination test based on a recombinant protein for diagnosis of cystic echinococcosis. Parasites & Vectors, Jul 2025. URL: https://doi.org/10.1186/s13071-025-06900-1, doi:10.1186/s13071-025-06900-1. This article has 1 citations and is from a peer-reviewed journal.

14. (petrone2024evaluationofthe pages 1-2): Linda Petrone, Saeid Najafi-Fard, Laura Falasca, Settimia Sbarra, Antonella Teggi, Emanuele Nicastri, Lucia Rosalba Grillo, Mirco Burocchi, Giuseppe Maria Ettorre, Alessandra Ludovisi, Daniele Colombo, Franca Del Nonno, and Delia Goletti. Evaluation of the local and peripheral immune responses in patients with cystic echinococcosis. Pathogens, 13:477, Jun 2024. URL: https://doi.org/10.3390/pathogens13060477, doi:10.3390/pathogens13060477. This article has 2 citations.

15. (petrone2024evaluationofthe pages 7-9): Linda Petrone, Saeid Najafi-Fard, Laura Falasca, Settimia Sbarra, Antonella Teggi, Emanuele Nicastri, Lucia Rosalba Grillo, Mirco Burocchi, Giuseppe Maria Ettorre, Alessandra Ludovisi, Daniele Colombo, Franca Del Nonno, and Delia Goletti. Evaluation of the local and peripheral immune responses in patients with cystic echinococcosis. Pathogens, 13:477, Jun 2024. URL: https://doi.org/10.3390/pathogens13060477, doi:10.3390/pathogens13060477. This article has 2 citations.

16. (tian2024globalregionaland pages 1-2): Tian Tian, Liyuan Miao, Wei Wang, and Xiaonong Zhou. Global, regional and national burden of human cystic echinococcosis from 1990 to 2019: a systematic analysis for the global burden of disease study 2019. Tropical Medicine and Infectious Disease, 9:87, Apr 2024. URL: https://doi.org/10.3390/tropicalmed9040087, doi:10.3390/tropicalmed9040087. This article has 29 citations.

17. (tenzin2024theburdenand pages 3-3): Chador Tenzin, Tashi Dendup, P. R. Torgerson, Peter Deplazes, Sonam Zangmo, Chador Wangmo, Tsheten Tsheten, and Tandin Zangpo. The burden and distribution of cystic echinococcosis in bhutan: a retrospective study. Parasitology, pages 1-9, Nov 2024. URL: https://doi.org/10.1017/s0031182024001069, doi:10.1017/s0031182024001069. This article has 1 citations and is from a peer-reviewed journal.

18. (erganis2024comparisonofmethods pages 4-6): Sidre Erganis, Fakhriddin Sarzhanov, Funda Doğruman Al, and Kayhan Cağlar. Comparison of methods in the serologic diagnosis of cystic echinococcosis. Acta Parasitologica, 69:1122-1131, Mar 2024. URL: https://doi.org/10.1007/s11686-024-00840-z, doi:10.1007/s11686-024-00840-z. This article has 18 citations and is from a peer-reviewed journal.

19. (bold2024thediagnosticchallenge pages 7-8): Bolor Bold, Christian Schindler, Uranshagai Narankhuu, Agiimaa Shagj, Erdenebileg Bavuujav, Sonin Sodov, Tsogbadrakh Nyamdorj, and Jakob Zinsstag. The diagnostic challenge of cystic echinococcosis in humans: first assessment of underreporting rates in mongolia. Tropical Medicine and Infectious Disease, Jul 2024. URL: https://doi.org/10.3390/tropicalmed9070163, doi:10.3390/tropicalmed9070163. This article has 6 citations.

20. (NCT05824442 chunk 1): Evaluation of a New Multiplex Quantitative PCR Technique for the Diagnosis of Echinococcosis. Centre Hospitalier Universitaire de Besancon. 2023. ClinicalTrials.gov Identifier: NCT05824442

21. (NCT05769790 chunk 1): Droplet-digital PCR for the Detection of Circulating Cell-free DNA in Patients With Cystic Echinococcosis: an Exploratory Study. IRCCS Sacro Cuore Don Calabria di Negrar. 2022. ClinicalTrials.gov Identifier: NCT05769790

22. (akhan2025theroleof pages 2-4): Okan Akhan and Turkmen Ciftci. The role of interventional radiology for the treatment of liver ce and ae lesions: current concepts. Visceral Medicine, pages 1-22, Jul 2025. URL: https://doi.org/10.1159/000547623, doi:10.1159/000547623. This article has 1 citations and is from a peer-reviewed journal.

23. (akhan2025theroleof pages 6-8): Okan Akhan and Turkmen Ciftci. The role of interventional radiology for the treatment of liver ce and ae lesions: current concepts. Visceral Medicine, pages 1-22, Jul 2025. URL: https://doi.org/10.1159/000547623, doi:10.1159/000547623. This article has 1 citations and is from a peer-reviewed journal.

24. (rosa2024followupstudy pages 1-2): Daniel Da Rosa, Elisa Figueredo, Michel Rosas, and Fernando Goñi. Follow up study of symptomatic human cystic echinococcosis treatment with albendazole and praziquantel, in uruguay. BMC Infectious Diseases, Jul 2024. URL: https://doi.org/10.1186/s12879-024-09539-y, doi:10.1186/s12879-024-09539-y. This article has 8 citations and is from a peer-reviewed journal.

25. (akhan2025theroleof media 3452c1f5): Okan Akhan and Turkmen Ciftci. The role of interventional radiology for the treatment of liver ce and ae lesions: current concepts. Visceral Medicine, pages 1-22, Jul 2025. URL: https://doi.org/10.1159/000547623, doi:10.1159/000547623. This article has 1 citations and is from a peer-reviewed journal.

26. (NCT06483880 chunk 1): The Role of Adjuvant Albendazole After Pulmonary Hydatid Cyst Resection. Ain Shams University. 2024. ClinicalTrials.gov Identifier: NCT06483880

27. (NCT01643018 chunk 1): Mehmet Kaplan. Laparoscopic Versus Open Surgery for the Management of Cystic Echinococcosis of the Liver. Medical Park Gaziantep Hospital. 2006. ClinicalTrials.gov Identifier: NCT01643018

28. (akhan2025theroleof pages 4-6): Okan Akhan and Turkmen Ciftci. The role of interventional radiology for the treatment of liver ce and ae lesions: current concepts. Visceral Medicine, pages 1-22, Jul 2025. URL: https://doi.org/10.1159/000547623, doi:10.1159/000547623. This article has 1 citations and is from a peer-reviewed journal.

29. (petrone2024evaluationofthe pages 2-3): Linda Petrone, Saeid Najafi-Fard, Laura Falasca, Settimia Sbarra, Antonella Teggi, Emanuele Nicastri, Lucia Rosalba Grillo, Mirco Burocchi, Giuseppe Maria Ettorre, Alessandra Ludovisi, Daniele Colombo, Franca Del Nonno, and Delia Goletti. Evaluation of the local and peripheral immune responses in patients with cystic echinococcosis. Pathogens, 13:477, Jun 2024. URL: https://doi.org/10.3390/pathogens13060477, doi:10.3390/pathogens13060477. This article has 2 citations.

30. (hogea2024cysticechinococcosisin pages 16-17): Mihai-Octav Hogea, Bogdan-Florin Ciomaga, Mădălina-Maria Muntean, Andrei-Alexandru Muntean, Mircea Ioan Popa, and Gabriela Loredana Popa. Cystic echinococcosis in the early 2020s: a review. Tropical Medicine and Infectious Disease, 9:36, Jan 2024. URL: https://doi.org/10.3390/tropicalmed9020036, doi:10.3390/tropicalmed9020036. This article has 74 citations.

31. (erganis2024comparisonofmethods pages 1-2): Sidre Erganis, Fakhriddin Sarzhanov, Funda Doğruman Al, and Kayhan Cağlar. Comparison of methods in the serologic diagnosis of cystic echinococcosis. Acta Parasitologica, 69:1122-1131, Mar 2024. URL: https://doi.org/10.1007/s11686-024-00840-z, doi:10.1007/s11686-024-00840-z. This article has 18 citations and is from a peer-reviewed journal.

32. (erganis2024comparisonofmethods pages 6-8): Sidre Erganis, Fakhriddin Sarzhanov, Funda Doğruman Al, and Kayhan Cağlar. Comparison of methods in the serologic diagnosis of cystic echinococcosis. Acta Parasitologica, 69:1122-1131, Mar 2024. URL: https://doi.org/10.1007/s11686-024-00840-z, doi:10.1007/s11686-024-00840-z. This article has 18 citations and is from a peer-reviewed journal.

33. (akhan2025theroleof pages 1-2): Okan Akhan and Turkmen Ciftci. The role of interventional radiology for the treatment of liver ce and ae lesions: current concepts. Visceral Medicine, pages 1-22, Jul 2025. URL: https://doi.org/10.1159/000547623, doi:10.1159/000547623. This article has 1 citations and is from a peer-reviewed journal.